Conway Jeannine M, White James R, Birnbaum Angela K, Eugene Ramsay R, Pennell Page B, Rarick John O, Musib Luna, Leppik Ilo E, Cloyd James C
Experimental and Clinical Pharmacology, University of Minnesota, 5-130 WDH, 308 Harvard St. S.E., Minneapolis, MN 55455, United States.
Epilepsy Res. 2009 Apr;84(2-3):242-4. doi: 10.1016/j.eplepsyres.2009.01.013. Epub 2009 Mar 18.
An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100mg of study drug as replacement for 100mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.
对113名年龄在19至87岁之间的癫痫患者（60名男性，53名女性）给予了卡马西平（CBZ）静脉制剂。受试者接受100mg研究药物，以替代其通常早上服用的100mg卡马西平。血压和心率没有显著变化，这表明该制剂可开发为无法口服卡马西平的患者的替代疗法。
